Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pruthvi Nagilla
Observed names:
Nagilla, Pruthvi,
Pruthvi S Nagilla
Institution:
University of Pittsburgh
Observed institution:
University of Pittsburgh
ORCID:
0009-0006-9019-9384
Observed ORCID:
0009-0006-9019-9384
OpenAlex ID:
A5058364977
MicroRNA regulation and its effects on cellular transcriptome in Human Immunodeficiency Virus-1 (HIV-1) infected individuals with distinct viral load and CD4 cell counts
2013
·
Karolina Duskova
, Pruthvi Nagilla
, et al.
·
BMC Infectious Diseases
·
82
PDF
Neuronal apoptosis by HIV-1 Vpr: contribution of proinflammatory molecular networks from infected target cells
2012
·
Debjani Guha
, Pruthvi Nagilla
, et al.
·
Journal of Neuroinflammation
·
70
PDF
Recommendations for Method Development and Validation of qPCR and dPCR Assays in Support of Cell and Gene Therapy Drug Development
2024
·
Amanda Hays
, Mark Wissel
, et al.
·
The AAPS Journal
·
59
PDF
Scavenger Receptor Function of Mouse Fcγ Receptor III Contributes to Progression of Atherosclerosis in Apolipoprotein E Hyperlipidemic Mice
2014
·
Xinmei Zhu
, Hang Pong Ng
, et al.
·
The Journal of Immunology
·
24
Correction: Comparative Expression Profile of miRNA and mRNA in Primary Peripheral Blood Mononuclear Cells Infected with Human Immunodeficiency Virus (HIV-1)
2012
·
Ankit Gupta
, Pruthvi Nagilla
, et al.
·
PLoS ONE
·
7
PDF
Velora pioneer, Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of HMB-002 for prophylaxis in von Willebrand disease: A trial in progress
2025
·
Priyanka Raheja
, Amy Knott
, et al.
·
Blood
·
2
PDF
Validation approach of an LC-MS/MS assay for ADA detection, applied to a Von Willebrand factor-targeted biotherapeutic
2026
·
Frank B. Schalk
, Kayla Shumate
, et al.
·
Bioanalysis
·
1
Validation approach of an LC-MS/MS assay for ADA detection, applied to a Von Willebrand factor-targeted biotherapeutic
2026
·
Schalk, Frank B.
, Shumate, Kayla
, et al.
·
Figshare
Early transgene expression of GALC enzyme in a phase I/II safety, tolerability and efficacy study of PBKR03 in infants with early infantile Krabbe disease (EIKD) (GALax-C)
2023
·
Samiah A. Al-Zaidy
, Nicole I. Wolf
, et al.
·
Molecular Genetics and Metabolism
Updated interim safety, biomarker, and efficacy data from Imagine-1: A phase 1/2 open-label, multicenter study to assess the safety, tolerability, and efficacy of a single dose, intra-cisterna magna (ICM) administration of PBGM01 in subjects with type I (early onset) and type IIA (late onset) infantile GM1 gangliosidosis (GM1)
2023
·
Jeanine R. Jarnes
, Caroline A. Hastings
, et al.
·
Molecular Genetics and Metabolism
Show more works
View as search
Works count:
11
Citation count:
301
H-index:
6
I10-index:
5
Year
Topic
Type